Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Landolfi
Raffaele
R
Di Gennaro
Leonardo
L
D001157:Arterial Occlusive Diseases / Q000209:etiology; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D000077144:Clopidogrel; D004176:Dipyridamole / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D053614:Janus Kinase 2 / Q000235:genetics; D015337:Multicenter Studies as Topic; D018962:Phlebotomy; D011087:Polycythemia Vera / Q000097:blood / Q000145:classification / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D013920:Thrombocythemia, Essential / Q000097:blood / Q000145:classification / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D019851:Thrombophilia / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D013927:Thrombosis / Q000517:prevention & control*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control
D004176:Dipyridamole; D000077144:Clopidogrel; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D013988:Ticlopidine; D001241:Aspirin; D006918:Hydroxyurea